Anti-aggregant activity of new xanthine derivative under conditions of hyper aggregation of platelets in vitro

Cover Page


Cite item

Abstract

Aim. To study the anti-aggregant activity and the effectiveness of firstly synthesized cyclohexilammonium salt of 2-[1-ethil-3-methyl-7-(dioxotiethanyl-3)-xantinyl-8-thio]acetic acid as a potential antiplatelet agent under in vitro conditions.

Methods. Experimental work was carried out on the blood of healthy donors and 74 male patients diagnosed with thrombosis of various localization. Thromboelastography of citrate blood samples was performed in the presence of the test substances on the device TEG 5000. The analysis determined the overall trend of coagulation, functional activity of platelets and fibrinogen, fibrinolytic activity and physico-mechanical properties of clots formed. ADP-, collagen-, and epinephrine-induced platelet aggregations were registered. Agregatogramm analysis was performed using software AGGR. We evaluated the general nature of the aggregation, the maximum aggregate, maximum aggregation rate, the average size of platelet aggregates.

Results. Cyclohexilammonium salt of 2-[1-ethil-3-methyl-7-(dioxotiethanyl-3)-xantinyl-8-thio]acetic acid in in vitro conditions showed anti-aggregant activity greater than the reference substance, and effectively suppress hypercoagulation caused by an excess of thrombin and tissue factor.

Conclusion. The results of the study make it possible to establish in a potentially high ex vivo therapeutic effect of a cyclohexilammonium salt of 2-[1-ethil-3-methyl-7-(dioxotiethanyl-3)-xantinyl-8-thio]acetic acid under conditions involving platelet hyperaggregation.

About the authors

A V Samorodov

Bashkir State Medical University, Ufa, Russia

Author for correspondence.
Email: avsamorodov@gmail.com

F Kh Kamilov

Bashkir State Medical University, Ufa, Russia

Email: avsamorodov@gmail.com

F A Khaliullin

Bashkir State Medical University, Ufa, Russia

Email: avsamorodov@gmail.com

Yu V Shabalina

Bashkir State Medical University, Ufa, Russia

Email: avsamorodov@gmail.com

G A Timirkhanova

Bashkir State Medical University, Ufa, Russia

Email: avsamorodov@gmail.com

D Z Muratayev

Bashkir State Medical University, Ufa, Russia

Email: avsamorodov@gmail.com

References

  1. Камилов Ф.Х., Тимирханова Г.А., Самородова А.И. и др. Антиагрегационная активность новой циклогексиламмониевой соли на основе 1-этилксантина на систему гемостаза в условиях in vitro // Казанский мед. ж. - 2013. - №5. - С. 692-695.
  2. Халиуллин Ф.А., Муртаев Д.З., Шабалина Ю.В. и др. Циклогексиламмониевая соль 2-[3-метил-7-(1,1-диоксотиетанил-3)-1-этилксантинил-8-тио]уксусной кислоты, проявляющая антитромбоэмболическое действие. Патент №2504546C1. Бюлл. №2 от 20.01.2014.
  3. Badimon J.J., Lettino M., Toschi V. et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of TFPI on plaque thrombogenicity under flow condition // Circulation. - 1999. - N 14. - P. 1780-1787.
  4. Воrn G.V. Aggregation of blood platelets by adenosine diphosphate and its reversal // Nature. - 1962. - Vоl. 194. - Р. 927-929.
  5. Khaliullin F.A., Shabalina Yu.V., Sharafutdinov R.M. Thietanil protection in synthesis of 1-alkyl-8-bromo-3-methyl-3,7-dihydro-1Н-purine-2,6-dions // Rus. J. Org. Chem. - 2010. - N 5. - P. 698-701.
  6. Markosian R.A. Method for analysis of blood platelet aggregations and apparatus therefor. Patents US5071247. 10.12.1991.
  7. Raskob G.E., Silverstein R., Bratzler D.W. et al. Surveillance for deep vein thrombosis and pulmonary embolism: Recommendations from a national workshop // Am. J. Prev. Med. - 2010. - N 38. - P. 502-509.
  8. Samorodov A., Kamilov F., Timirkhanova G. et al. Antithrombotic activity of new 1-ethylxanthine cyclohexylammonium salt // FASEB J. - 2014. - N 28. - 1054.5.

© 2015 Samorodov A.V., Kamilov F.K., Khaliullin F.A., Shabalina Y.V., Timirkhanova G.A., Muratayev D.Z.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.





This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies